Free Trial
NASDAQ:JAGX

Jaguar Animal Health Q3 2025 Earnings Report

Jaguar Animal Health logo
$2.12 -0.15 (-6.61%)
Closing price 04:00 PM Eastern
Extended Trading
$2.25 +0.13 (+6.13%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jaguar Animal Health EPS Results

Actual EPS
N/A
Consensus EPS
-$5.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Jaguar Animal Health Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jaguar Animal Health Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Jaguar Animal Health Earnings Headlines

Jaguar Health Completes Private Placement Deal
This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
Jaguar Health Completes Private Placement Deal
See More Jaguar Animal Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email.

About Jaguar Animal Health

Jaguar Animal Health (NASDAQ:JAGX) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding. The company is headquartered in East Windsor, New Jersey, and maintains a streamlined development organization designed to advance lead candidates from proof-of-concept through regulatory approvals and commercial launch.

Among Jaguar’s key offerings is a proprietary probiotic formulation intended to reduce the incidence and severity of post-weaning diarrhea in piglets, which has received regulatory clearance in select markets. In parallel, the company is progressing a complementary feed-additive candidate for controlling necrotic enteritis in broiler chickens. Jaguar leverages in-house expertise in microbial therapeutics to optimize dosing regimens and demonstrate consistent performance under commercial farming conditions.

To date, Jaguar Animal Health serves customers primarily in Latin America through strategic distribution partnerships, while preparing for broader market entry in North America. The company’s leadership team brings experience in veterinary development, regulatory affairs, and commercial operations, positioning Jaguar to address growing global demand for effective, antibiotic-reducing solutions in livestock production.

View Jaguar Animal Health Profile

More Earnings Resources from MarketBeat